Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces - 2Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- 35 Instructive Toy Brands for Youngsters
- 4Step by step instructions to Pick A Pre-owned vehicle Stage
- 5UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- Family Holiday spots
- At least 171 measles cases confirmed in 9 states, CDC data shows
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- Embracing Practical Living and Ecological Protection
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
